A drug for treating hepatitis B virus (HBV) could be mass-produced at a fraction of its current price - for only $36 (Rs.2,267) per person per year, versus the current US price of over $15,000 (Rs. 944,775), say University of Liverpool researchers in Britain.
Hepatitis B causes liver cancer and liver cirrhosis, both of which can be fatal. It is transmitted through blood and infected bodily fluids. There is also a risk of infected mothers passing on the Hepatitis B virus to their children.
Amitabh Bachchan Offers Support to Government Campaign on Hepatitis B
Bachchan and his wife and Rajya Sabha member Jaya Bachchan met Health Minister J.P. Nadda and expressed interest to spread awareness on various health issues.
Advertisement
"We have shown that the Hepatitis B drug, entecavir, could be mass produced for only $36 per person per year. Combining mass vaccination with mass treatment would lead to huge reductions in the number of people being infected with Hepatitis B, and could significantly lower the death rates from the current 686,000 per year worldwide," said Andrew Hill, senior visiting research fellow.
The researchers analyzed the factors which influence the cost of manufacturing of drugs for hepatitis B, including the cost of the raw materials, the amount of drug needed and the patent situation of each drug.
![Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma]( "Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma")
Hepatocellular carcinoma is one of the few cancers in which a continued increase in incidence has been observed over recent years.
They found that the drug entecavir (Baraclude, Bristol Myers Squibb) has the potential to be mass produced as a generic drug at a fraction of its current price which would mean that all countries, including poorer/developing countries, could afford to use it.
Entecavir is an effective antiviral drug used in the treatment of HBV infection with few adverse side effects to patients, low levels of resistance.
The dose is only 0.5 milligrams per day, so only a fifth of a gram would need to be produced to provide a year's supply. This is one reason why this drug is so cheap to manufacture.
Currently, entecavir is the most expensive drug for hepatitis B on the market in both developed and developing countries.
However, the expiration of its patent in February 2015 in the US and other countries, which means it could now be manufactured as a generic drug by other companies at a far lower cost.
The study appeared in the Journal of Virus Eradication.
Source: IANS
Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the few cancers in which a continued increase in incidence has been observed over recent years.
Advertisement
They found that the drug entecavir (Baraclude, Bristol Myers Squibb) has the potential to be mass produced as a generic drug at a fraction of its current price which would mean that all countries, including poorer/developing countries, could afford to use it.
Entecavir is an effective antiviral drug used in the treatment of HBV infection with few adverse side effects to patients, low levels of resistance.
The dose is only 0.5 milligrams per day, so only a fifth of a gram would need to be produced to provide a year's supply. This is one reason why this drug is so cheap to manufacture.
Currently, entecavir is the most expensive drug for hepatitis B on the market in both developed and developing countries.
However, the expiration of its patent in February 2015 in the US and other countries, which means it could now be manufactured as a generic drug by other companies at a far lower cost.
The study appeared in the Journal of Virus Eradication.
Source: IANS
Researchers Find Way to Sustain Hepatitis B in Human Liver Cells
Researchers led by MIT's Sangeeta Bhatia and Charles Rice of Rockefeller University revealed that they were able to sustain hepatitis B virus in human liver cells.
Advertisement
Risk of Liver Cancer Lower Among Chronic Hepatitis B Patients Who Undergo Antiviral TherapyUndergoing antiviral therapy can reduce the risk of liver cancer among patients who have chronic hepatitis B infection. | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Safety and effectiveness of commonly used painkillers (analgesics) for short-term relief of low back pain remain uncertain.
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.